Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug

References

1. ↵
   1. Goyal R,
   2. Devi SH

   (2014) A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up. Clin Psychopharmacol Neurosci 12, 69–71.
2. ↵
   1. Waln O,
   2. Jankovic J

   (2013) An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y), 3, pii:tre-03-161-4138-1.
3. ↵
   1. Saltz BL,
   2. Robinson DG,
   3. Woerner MG

   (2004) Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry 6, Suppl 2, S14–S19.
4. ↵
   1. American Psychiatric Association

   (2013) Diagnostic and statistical manual of mental disorders, (DSM-5) (American Psychiatric Association, Arlington, (VA)), 5th ed, 712.
5. ↵
   1. Kim J,
   2. MacMaster E,
   3. Schwartz TL

   (2014) Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context 3, 212259.
6. ↵
   1. Schneider SA,
   2. Aggarwal A,
   3. Bhatt M,
   4. Dupont E,
   5. Tisch S,
   6. Limousin P,
   7. et al.

   (2006) Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 67, 940–943.
7. ↵
   1. Yoshida K,
   2. Bies RR,
   3. Suzuki T,
   4. Remington G,
   5. Pollock BG,
   6. Mizuno Y,
   7. et al.

   (2014) Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophr Res 153, 184–188.
8. ↵
   1. Go CL,
   2. Rosales RL,
   3. Caraos RJ,
   4. Fernandez HH

   (2009) The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord 15, 655–659.
9. ↵
   1. Connor DF,
   2. Fletcher KE,
   3. Wood JS

   (2001) Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62, 967–974.
10. ↵
    1. Bhidayasiri R,
    2. Boonyawairoj S

    (2011) Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 87, 132–141.
11. ↵
    1. Bhidayasiri R,
    2. Fahn S,
    3. Weiner WJ,
    4. Gronseth GS,
    5. Sullivan KL,
    6. Zesiewicz TA,
    7. et al.

    (2013) Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81, 463–469.
12. ↵
    1. Richardson MA,
    2. Bevans ML,
    3. Read LL,
    4. Chao HM,
    5. Clelland JD,
    6. Suckow RF,
    7. et al.

    (2003) Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 160, 1117–1124.
13. ↵
    1. Kim J,
    2. Donovan J,
    3. Schwartz TL

    (2014) Dextromethorphan for tardive dyskinesia. International Neuropsychiatric Disease Journal 2, 136–140.
14. ↵
    1. Woods SW,
    2. Saksa JR,
    3. Baker CB,
    4. Cohen SJ,
    5. Tek C

    (2008) Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 69, 546–554.
15. ↵
    1. Pappa S,
    2. Tsouli S,
    3. Apostolou G,
    4. Mavreas V,
    5. Konitsiotis S

    (2010) Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33, 271–275.